FilingSEC EDGAR8-K
Tempest Therapeutics Enters Service Agreement with Related Party and Appoints New Executives
· SEC accepted
StageOperations
Filing content
Tempest Therapeutics entered into a $5 million annual research and development services agreement with Factor Bioscience and appointed Nancy Freda-Smith to its board and a new CFO.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…